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Abstract	
3,4-dihydroxy-L-phenylalanine	(L-DOPA)	is	the	gold	standard	treatment	for	Parkinson’s	
disease.	It	has	earned	that	title	through	its	highly	effective	treatment	of	some	of	the	motor	
symptoms	in	the	early	stages	of	the	disease	but	it	is	a	far	from	perfect	drug.	The	inevitable	
long	term	treatment	that	comes	with	this	chronic	neurodegenerative	condition	raises	the	
risk	significantly	of	the	development	of	motor	fluctuations	including	disabling	L-DOPA-
induced	dyskinesia.		Being	unsurpassed	as	a	therapy	means	that	understanding	the	
mechanisms	of	dyskinesia	priming	and	induction	is	vital	to	the	search	for	therapies	to	treat	
these	side	effects	and	allow	optimal	use	of	L-DOPA.	However,	L-DOPA	use	may	also	have	
consequences	(positive	or	negative)	for	the	development	of	other	interventions,	such	as	cell	
transplantation,	which	are	designed	to	treat	or	repair	the	ailing	brain.		This	review	looks	at	
the	issues	around	the	use	of	L-DOPA	with	a	focus	on	its	potential	impact	on	advanced	
reparative	interventions.	
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Introduction	
At	little	over	200	years	since	James	Parkinson’s	first	description	of	the	symptoms	of	‘the	
Shaking	Palsy’	(Parkinson,	1817),	it	is	also	60	years	since	Arvid	Carlsson’s	experiments	
showing	the	positive	effects	of	the	aromatic	amino	acid,	dopamine	precursor,	3,4-
dihydroxy-L-phenylalanine	(L-DOPA)	in	a	rodent	model	of	akinesia	(Carlsson	et	al.,	1957).	
The	reports	that	followed	of	early	attempts	to	treat	Parkinson’s	disease	in	patients	with	D/L-
DOPA	intravenously	had	varied	outcomes	(Birkmayer	&	Hornykiewicz,	1961).	Persistence	
paid	off,	and	the	discovery	that	oral	administration	of	D/L-DOPA,	slowly	titrated	up,	allowed	
much	bigger,	more	clinically	effective	doses	to	be	administered	(Cotzias	et	al.,	1967).	Two	
further	refinements	to	the	approach	led	to	success;	selectively	administering	the	active	
isomer	L-DOPA,	and	the	co-administration	with	a	peripheral	amino	acid	decarboxylase	
inhibitor.	These	contributed	to	further	minimising	the	side	effects	of	peripheral	conversion	
to	dopamine	and	improved	efficacy	by	enhancing	passage	across	the	blood	brain	barrier	
(Cotzias,	1968;	Cotzias	et	al.,	1969a;	b;	Papavasiliou	et	al.,	1972).		This	provided	a	more	
consistent	and	sustained	beneficial	outcome	with	the	management	of	the	gastrointestinal	
side	effects	that	had	thwarted	its	use	in	earlier	studies	(Cotzias	et	al.,	1969b;	Papavasiliou	et	
al.,	1972).	Revolutionising	treatment	for	Parkinson’s	disease,	L-DOPA	rapidly	became,	and	
has	remained,	the	‘gold	standard’	therapy	for	Parkinson’s	disease.	Nevertheless,	throughout	
this	period,	its	optimal	use	has	continued	to	be	debated.	There	is	no	doubt	in	the	
remarkable	ability	of	this	drug	to	alleviate	the	motor	symptoms	of	the	disease	and	it	is	a	
vital	cornerstone	of	current	pharmacotherapy.	Yet	it	is	a	drug	with	two	sides,	and	ongoing	
controversies	over	the	decades	of	its	use	have	largely	centred	on	the	development	of	motor	
fluctuations	which	occur	with	high	dose	and/or	long	term	therapy.	Moreover,	given	that	
patients	entering	clinical	trials	will	inevitably	be	on	L-DOPA	therapy,	it	is	important	that	L-
DOPA	and	its	side	effects	are	considered	preclinically	as	factors	in	the	search	for	new	
therapeutic	or	disease	modifying	strategies.	This	is	exemplified	in	the	case	of	foetal	cell	
transplantation,	in	which	patients	developed	an	intractable	form	of	dyskinesia	as	an	
apparent	direct	result	of	the	surgically	delivered	reparative	intervention,	that	has	been	
linked	to	pre-treatment	with	L-DOPA.	This	review	highlights	the	therapeutic	effects	of	L-
DOPA	in	the	treatment	of	Parkinson’s	disease,	moving	on	to	discuss	the	issues	of	L-DOPA-
induced	complications.	Importantly,	the	role	L-DOPA	and	dyskinesia	play	in	the	context	of	
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newly	developed	therapies	will	be	emphasised	and	discussed	as	a	consideration	for	future	
interventions.	
	
L-DOPA	in	the	clinical	management	of	Parkinson’s	disease	
The	cardinal	symptoms	of	Parkinson’s	disease	are	generally	still	recognised	as	those	
described	by	James	Parkinson,	bradykinesia/akinesia,	resting	tremor,	postural	instability	and	
muscular	rigidity	(Parkinson,	1817).	Prior	to	the	development	of	L-DOPA,	there	was	a	very	
limited	choice	of	medical	interventions	to	alleviate	any	of	these	symptoms.	The	
anticholinergic	drugs,	muscarinic	receptor	antagonists,	are	still	available	for	use	today	but	
have	limited	ability	to	treat	the	motor	symptoms,	are	troublesome	to	administer	in	the	
elderly	and	come	with	a	host	of	cholinergic	side	effects.		L-DOPA	revolutionised	the	
treatment	of	PD,	improving	the	cardinal	symptoms	of	rigidity	and	bradykinesia	as	well	as	
functional	disability	although	with	more	limited	effects	on	tremor	(Godwin-Austen	et	al.,	
1969).	These	positive	effects	reinforced	the	hypothesis	derived	from	the	pathology	of	the	
disease,	that	many	of	the	symptoms	(although	not	all)	were	dopaminergic	in	origin	
(Bernheimer	et	al.,	1973).		The	addition	of	carbidopa,	or	latterly	benserazide,	as	peripheral	
aromatic	amino	acid	decarboxylase	inhibitors	reduced	the	dose	required	for	beneficial	
effects	and	gave	better	control	of	motor	symptoms,	along	with	a	reduction	in	the	
cardiovascular	and	gastrointestinal	side	effects.		
	
L-DOPA	is	transported	through	the	blood	brain	barrier	on	the	large	amino	acid	transporter	1	
(LAAT1)	where	it	is	taken	up	into	dopaminergic	terminals	and	converted	into	dopamine	by	
the	enzyme	aromatic	amino	acid	decarboxylase.	There	are	two	components	to	the	resulting	
clinical	response,	known	as	the	short-duration	and	long-duration	responses.		The	
immediate,	relatively	short-lived	(2-3	h)	improvement	in	motor	symptoms	of	the	short-
duration	response	parallels	the	plasma	levels	of	L-DOPA.	The	longer	duration	response	
builds	up	over	several	days	or	even	weeks,	such	that	the	maximal	effects	of	L-DOPA	can	take	
several	months.	Following	cessation	of	treatment,	estimates	in	the	decline	of	the	long-
duration	response	following	L-DOPA	withdrawal	vary	from	days	to	weeks	depending	on	the	
study	(Muenter	&	Tyce,	1971;	Fahn	et	al.,	2004).	During	the	first	1–3	years	of	therapy	the	
clinical	response,	measured	as	the	ON-phase	and	dubbed	the	“honeymoon	period”,	is	
relatively	constant.	It	is	likely	that	the	long	duration	response	in	dominating	through	this	
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period	and	is	thought	to	contribute	to	at	least	half	the	overall	L-DOPA	response	(Nutt	et	al.,	
1997;	Fahn	et	al.,	2004).	Quality	of	life	is	significantly	enhanced	from	the	use	of	L-DOPA	as	
pharmacotherapy	clinical	benefit	over	dopamine	agonists	in	symptom	alleviation.	In	fact	
demonstrable	L-DOPA	responsiveness	is	such	a	defining	feature	of	the	disease	that	it	forms	
a	part	of	the	diagnostic	criteria	(Postuma	et	al.,	2015).		As	the	disease	advances	
responsiveness	to	L-DOPA	declines	but	as	doses	increases,	this	is	coincident	with	more	rapid	
reductions	in	efficacy	at	the	end	of	dose	known	as	‘OFF-phase’	(Fabbri	et	al.,	2016).		A	drug	
that	has	been	used	widely	for	50	years	nevertheless,	questions	still	remain	over	its	full	
mechanism	of	action	beyond	conversion	to	dopamine,	as	other	metabolic	products	of	L-
DOPA	have	been	shown	to	have	possible	glutamatergic	activity,	unrelated	to	the	dopamine	
synthesis	(Guatteo	et	al.,	2013;	De	Deurwaerdere	et	al.,	2017)	
	
L-DOPA	mediated	toxicity	
The	question	as	to	whether	L-DOPA	treatment	could	impact	on	disease	progression	or	
mortality	arose	very	early	in	its	clinical	use.	Given	that	L-DOPA	can	be	converted	to	highly	
reactive	semiquinone	and	quinone	derivatives,	and	that	the	metabolism	of	the	dopamine	
that	is	produced	could	contribute	to	oxidative	stress	through	the	Fenton	reaction	(Smith	et	
al.,	1994),	there	was	a	concern	over	neurotoxicity	with	several	early	studies	seeking	to	
determine	whether	L-DOPA	itself	may	contribute	to	disease	pathophysiology	(Barbeau	&	
Roy,	1976;	Rajput	et	al.,	1997;	Melamed	et	al.,	1998).	Certainly	in	vitro	determination	of	
cellular	toxicity	illustrated	that	L-DOPA	and	dopamine	can	be	detrimental	to	cell	survival	(Ziv	
et	al.,	1997;	Mytilineou	et	al.,	2003),	but	in	vivo	studies	did	not	consistently	support	this	
finding	(Camp	et	al.,	2000;	Datla	et	al.,	2001;	Ferrario	et	al.,	2003;	Mytilineou	et	al.,	2003).	
As	a	result,	and	with	inconclusive	clinical	attempts	to	address	this,	the	clinical	relevance	of	
the	preclinical	findings	was	in	question.	Eventually	a	large	clinical	cohort	study,	ELLDOPA,	
found	no	evidence	of	an	impact	of	L-DOPA	on	disease	progression	(Fahn	et	al.,	2004).				
	
Other	studies	focused	on	the	role	of	L-DOPA	in	mortality	in	Parkinson’s	disease,	the	most	
recent	of	which	have	not	demonstrated	any	reduction	in	mortality	directly	associated	with	
the	use	of	L-DOPA,	although	they	concomitantly	highlight	limited	benefit	(Di	Rocco	et	al.,	
1996;	1998;	Hely	et	al.,	1999;	Montastruc	et	al.,	2001;	Rascol	et	al.,	2006).	In	those	studies	
that	do	show	improvements	in	mortality	rates,	the	focus	is	largely	on	early	stage,	
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uncomplicated	PD,	suggesting	that	the	most	benefit	is	seen	during	the	‘honeymoon	period’	
(Matarazzo	et	al.,	2018).	Overriding	factors	that	do	increase	mortality	rate,	determined	in	
long	running	studies	of	up	to	15	years,	are	unrelated	to	medication	and	pertain	to	incidence	
of	dementia	and	the	age	of	onset	of	the	disease	(Hely	et	al.,	1999;	Montastruc	et	al.,	2001).	
	
L-DOPA	mediated	complications	
Acutely	L-DOPA	causes	side	effects	of	orthostatic	hypotension,	excessive	daytime	
somnolence	and	nausea.	These	are	generally	well	tolerated	by	patients	but	as	the	disease	
advances	the	use	of	L-DOPA	becomes	more	complex;	some	symptoms	become	resistant	to	
the	treatment	and	motor	fluctuations	are	a	major	feature	of	the	clinical	management.	The	
phenomena	of	freezing,	wearing	off	and	L-DOPA	induced	dyskinesia	(LID)	as	side	effects	of	
long	term,	high	dose	L-DOPA	use	were	recognised	as	very	early	on	in	its	clinical	use	(Cotzias	
et	al.,	1969b;	Barbeau,	1971).	Although	the	fluctuations	between	ON	and	OFF	states,	are	
distressing	and	disabling,	the	treatment	limiting	side	effect	of	L-DOPA	is	the	abnormal	
involuntary	movements	known	as	LID.		LID	occur	as	choreic	and/or	dystonic	movements;	
chorea	being	abnormal,	purposeless,	non-rhythmic,	rapid	movements	commonly	affecting	
the	neck	and	limbs	while	dystonia	are	sustained	contractions	of	muscles,	which	may	be	
localised	to	specific	muscle	groups.	LID	appear	as	either	peak	dose	or	diphasic/end-of-dose	
dyskinesia	which	have	distinct	temporal	profiles	in	relation	to	each	dose	of	L-DOPA.	Most	
troublesome	are	the	peak	dose	dyskinesia,	occurring	during	the	peak	plasma	concentration	
of	L-DOPA,	while	the	diphasic	dyskinesia	occur	at	low	L-DOPA	levels	at	the	start	and	end	of	
the	dose	of	L-DOPA.	
	
A	retrospective	cumulative	literature	synthesis	of	data	on	the	frequency	of	LID	development	
across	clinical	trial	cohorts,	found	that	within	the	first	year	of	treatment	very	few	patients	
experienced	dyskinesia	(Ahlskog	&	Muenter,	2001).	They	identified	a	frequency	of	
dyskinesia	of	around	40%	by	4-6	years	of	L-DOPA	treatment,	reaching	90%	within	9	years	of	
L-DOPA	treatment	with	a	similar	profile	for	motor	fluctuations	(Ahlskog	&	Muenter,	2001).	
Although	a	view	not	consistently	held,	with	the	more	widespread	use	of	dopamine	agonists	
in	the	1980s	and	1990s	came	the	trend	for	delayed	use	of	L-DOPA	in	favour	of	these	
alternatives.		The	principle	was	that	by	sparing	the	use	of	L-DOPA,	the	onset	of	LID	would	be	
delayed.	However,	a	prospective	study	comparing	initial	treatment	with	either	the	
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dopamine	agonist	ropinirole	or	L-DOPA	confirmed	that	although	dyskinesia	incidence	was	
less	on	ropinirole,	once	L-DOPA	therapy	commenced	there	was	no	beneficial	delay	in	
dyskinesia	onset	(Rascol	et	al.,	2000;	Hauser	et	al.,	2007).		Similar	findings	were	reported	in	
the	long	running	PDRG-UK	following	patients	initially	randomised	to	L-DOPA,	L-DOPA	plus	
selegiline	or	the	dopamine	agonist	bromocriptine	(Katzenschlager	et	al.,	2008).	Dopamine	
agonists	also	carry	the	risk	of	impulse	control	disorders	and	are	less	effective	at	alleviating	
symptoms	particularly	at	later	stages	of	the	disease.		Current	guidance	is	that	low	dose	L-
DOPA	should	be	considered	as	an	option	from	the	onset	of	pharmacotherapy	alongside	
dopamine	agonists	and	monoamine	oxidase	B	inhibitors.		
	
Risk	factors	for	L-DOPA	induced	dyskinesia	
Evidence	that	LID	are	related	predominantly	to	the	severity	of	striatal	dopaminergic	
denervation	comes	from	multiple	avenues.	Patients	affected	by	the	neurotoxin	1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine	(MPTP)	who	had	experienced	rapid	and	severe	
nigrostriatal	denervation,	developed	similarly	rapid	LID	onset	after	L-DOPA	treatment	was	
initiated	(Langston	&	Ballard,	1984;	Ballard	et	al.,	1985).	Moreover,	with	PD	often	being	an	
asymmetric	disorder,	the	side	of	the	body	most	affected	by	the	disease	is	likely	to	be	the	
first	to	be	affected	by	the	LID	(Ruzicka	et	al.,	2005).		Disease	duration	is	a	major	risk	variable	
as	is	dose	of	L-DOPA	but	both	are	linked	to	disease	severity,	L-DOPA	dose	being	higher	in	
more	severely	affected	patients	(Cilia	et	al.,	2014).		Rodent	and	primate	studies	support	
these	findings,	demonstrating	that	LID	following	chronic	L-DOPA	are	only	produced	in	
animals	with	severe	denervation	but	highlight	that	this	is	not	the	only	determinant	(Di	
Monte	et	al.,	2000;	Guigoni	et	al.,	2005;	Lindgren	et	al.,	2007).		
	
There	are	other	identified	risk	factors	for	LID,	with	a	strong	association	with	age	at	onset	of	
Parkinson’s,	with	younger	patients	(roughly	defined	as	under	50	at	disease	onset)	having	an	
increased	risk	(Warren	Olanow	et	al.,	2013;	Zhang	et	al.,	2013),	although	this	may	be	
explained	by	factors	other	than	age	per	se	including	that	earlier	onset	of	disease	is	linked	to	
higher	degree	of	dopamine	denervation	at	disease	onset,	higher	dopamine	turnover	and	
enhanced	dopamine	receptor	signalling	(de	la	Fuente-Fernandez	et	al.,	2004;	Sossi	et	al.,	
2006;	Troiano	et	al.,	2009).		The	akinetic-rigid	Parkinson’s	phenotype	has	been	linked	to	
higher	risk	over	the	tremor	dominant	phenotypes	but	is	again	linked	to	more	severe	striatal	
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dopaminergic	denervation	(Zhang	et	al.,	2013).	Weight	and	gender	have	been	identified	as	
risk	factors	in	some	studies	but	the	evidence	is	less	consistent	(Sharma	et	al.,	2010;	Hassin-
Baer	et	al.,	2011;	Warren	Olanow	et	al.,	2013).		Genetics	variants	in	the	dopaminergic	
machinery	are	also	associated	with	altered	LID	risk,	including	genes	encoding	dopamine	
receptors,	the	dopamine	transporter,	catechol-o-methyl	transferase,	and	monoamine	
oxidase	(Comi	et	al.,	2017;	Kusters	et	al.,	2018;	Sampaio	et	al.,	2018).		
	
Patients	themselves	have	a	mixed	relationship	with	L-DOPA	for	these	reasons.	Caution	on	
behalf	of	the	medical	profession,	combined	with	patients	reluctant	to	increase	their	dose	in	
attempts	to	minimise	the	onset	of	LID,	may	lead	to	patients	not	receiving	the	full	benefit	
they	could	have	from	L-DOPA.	However,	it	has	been	reported	that	once	patients	reach	this	
stage	and	experience	dyskinesia,	they	find	it	more	acceptable	than	bradykinesia	and	
reduced	efficacy	of	lower	doses	(Hung	et	al.,	2010;	Hattori	et	al.,	2012).	The	impact	of	LID	on	
quality	of	life	is	generally	negative	but	varies	from	study	to	study	(Pechevis	et	al.,	2005;	
Rahman	et	al.,	2008;	Montel	et	al.,	2009;	Politis	et	al.,	2010b),	but	in	addition	they	are	
associated	with	increased	risk	of	falls	and	depression	(Ashburn	et	al.,	2001;	Pechevis	et	al.,	
2005)	.		
	
Pathophysiology	of	L-DOPA–induced	dyskinesia	
In	early	disease,	the	few	intact	dopaminergic	neurons	remaining	are	still	able	to	store	
dopamine,	and	regulate	its	release	through	the	feedback	dopamine	D2	autoreceptors	in	the	
pre-synaptic	membrane.	This,	along	with	some	remaining	dopamine	transporter	activity	
limits	excessive	post-synaptic	DA	receptor	stimulation.	However,	as	dopaminergic	terminals	
are	lost	through	disease	progression	(Vermeulen	et	al.,	1995),	the	short	duration	response	
begins	to	dominate	with	greater	fluctuations	in	function	as	plasma	levels	of	L-DOPA	peak	
and	trough.		With	the	reduced	ability	of	dopaminergic	terminals	to	convert	L-DOPA	to	
dopamine,	L-DOPA	handling	and	the	subsequent	synthesis	and	regulation	of	dopamine	in	
the	striatum	is	now	occurring	in	non-dopaminergic	5-HT	terminals	which	also	contain	the	
required	synthesis	machinery	(aromatic	amino	acid	decarboxylase),	but	lack	the	regulatory	
controls	(D2	autoreceptors)	(Carta	&	Tronci,	2014).	Imaging	data	indicates	that	there	is	in	
fact	increased	5-HT	striatal	innervation	in	dyskinetic	patients,	as	opposed	to	those	who	have	
a	stable	response	to	L-DOPA,	both	greater	pallidal	serotonergic	innervation	and	greater	5-
	 10	
HT	transporter/dopamine	transporter	ratios	(Politis	et	al.,	2014;	Smith	et	al.,	2015;	
Roussakis	et	al.,	2016)	indicating	a	significant	role	for	the	serotonin	system	in	LID.	The	lack	
of	dopaminergic	autoreceptors	on	the	5-HT	terminals	leads	to	abnormal	presynaptic	
dopamine	handling	and	thereby	dysregulated	dopamine	release.	
	
An	additional	key	feature	of	LID	is	that	they	become	intractable.	Once	LID	are	established	
the	relationship	to	dose	of	L-DOPA	becomes	less	linear	and	L-DOPA	holidays	have	no	
significant	benefit	in	reducing	LID	clinically.	This	priming	effect	is	mirrored	in	both	MPTP-
treated	non-human	primates	and	6-OHDA-lesioned	rodents	treated	chronically	with	L-
DOPA.	Both	models	have	severe	denervation	of	the	nigrostriatal	pathway	and	chronic	L-
DOPA	administration	leads	to	the	development	of	abnormal	involuntary	movements	likened	
to	LID	phenomenologically	and	biochemically	(Bedard	et	al.,	1986;	Clarke	et	al.,	1987;	
Doucet	et	al.,	1996;	Cenci	et	al.,	1998;	Cenci	et	al.,	1999).	Pharmacologically	the	LID	
generated	are	responsive	to	amantadine	as	seen	in	clinical	settings	(Blanchet	et	al.,	1998;	
Lundblad	et	al.,	2002).	These	models	serve	as	useful	exploratory	tools	to	understand	the	
mechanisms	underlying	LID	and	in	the	search	for	new	treatment	strategies	which	would	
allow	L-DOPA	to	be	utilised	to	its	full	potential	throughout	the	disease	(reviewed	in	this	
volume	Fox	and	Brotchie	2018).	With	the	use	of	these	models,	alongside	the	growing	
knowledge	of	clinical	risk	factors	and	how	this	might	relate	to	the	pathophysiology	of	the	
condition,	a	picture	is	growing	of	the	long-term	changes	that	evolve	during	chronic	L-DOPA	
administration	and	temporally	associate	with	LID	induction	and	severity.		The	fluctuations	in	
striatal	dopamine	levels	caused	by	serotonergic	handling	of	the	L-DOPA	have	consequences	
for	the	control	of	post-synaptic	medium	spiny	neurons:	excitatory	D1	dopamine	receptor	
containing	medium	spiny	neurons	of	the	direct	basal	ganglia	pathway	or	the	inhibitory	D2	
expressing	cells	of	the	indirect	pathway	(see	figure	1).		Originally	described	by	Albin	et	al	
1989,	the	basal	ganglia	circuitry	is	affected	by	the	loss	of	dopamine	in	the	disease,	in	which	
the	dysregulation	of	the	output	nuclei	(globus	pallidus	interna	and	substantia	nigra	pars	
reticulata)	leads	to	reduced	motor	cortex	output.	L-DOPA	induced	dyskinesia	arise	through	
the	excessive	activity	at	the	output	nuclei	disinhibiting	the	thalamus	leading	to	excessive	
cortical	stimulation	(see	figure	1,	this	is	excellently	and	extensively	reviewed	elsewhere	
(Bastide	et	al.,	2015;	Cenci	et	al.,	2018).		
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Dopaminergic	receptor	dysregulation	is	heavily	evidenced,	as	are	the	underlying	ERK	and	
cAMP	pathways	(Westin	et	al.,	2001;	Westin	et	al.,	2007;	Lebel	et	al.,	2010;	Park	et	al.,	2014)	
Studies	of	these	pathways	alongside	recent	chemogenetic	manipulation	of	specific	cell	types	
supports	the	notion	that	altered	dopaminergic	activity	at	the	D1	and	D2	receptors	drives	the	
abnormal	movements	(Aubert	et	al.,	2005;	Gold	et	al.,	2007;	Guigoni	&	Bezard,	2009;	
Alcacer	et	al.,	2017).		Immediate	early	gene	expression	in	the	postsynaptic	medium	spiny	
neurons	is	elevated	following	chronic	L-DOPA	administration,	extracellular	signal-related	
protein	kinase	(ERK)	and	mitogen	and	stress	activating	factor-1	(MSK1)	are	involved	in	the	
increased	expression	of	DfosB,	which	is	highly	correlated	to	LID	expression	in	rodent	and	
primate	models	(Andersson	et	al.,	1999;	Cenci	et	al.,	1999;	Valastro	et	al.,	2007;	Lindgren	et	
al.,	2011).	This	is	a	long-term	upregulation	which	appears	to	be	causally	related	to	LID	
expression	and	intractability,	with	functional	inactivation	reducing	dyskinesia	in	the	rodent	
model	whilst	conversely	overexpression	of	its	dimerising	partner	JunD	has	the	same	effect	
(Berton	et	al.,	2009;	Feyder	et	al.,	2016).	
Long	term	L-DOPA	treatment	and	the	development	of	LID	also	cause	other	alterations	to	
basal	ganglia	circuitry	(Rylander	Ottosson	&	Lane,	2016).	The	corticostriatal	synapse	
between	the	glutamatergic	cortical	efferent	and	striatal	MSNs	is	an	essential	pathway	for	
improvement	in	motor	function	after	L-DOPA	administration.	Both	long	term	potentiation	
(LTP)	and	long	term	depotentiation	(LTD)	are	key	features	of	excitatory	corticostriatal	
synapses	where	they	are	believed	to	underlie	motor-skilled	learning,	cognitive	performance	
and	reward	mechanisms	(Calabresi	et	al.,	2007).	In	rats	with	dopaminergic	denervation,	
both	LTP	and	LTD	are	absent	or	severely	altered	(Picconi	et	al.,	2003;	Paille	et	al.,	2010)	and	
restoration	of	LTP	has	been	seen	in	the	dorsolateral	striatum	with	repeated	L-DOPA	
administration	(Picconi	et	al.,	2003).		In	both	rodent	models	and	in	patients	with	LID,	
aberrant	corticostriatal	plasticity	has	been	demonstrated	(Morgante	et	al.,	2006;	Calabresi	
et	al.,	2007).	In	the	rat	PD	model,	LID	is	associated	with	an	irreversible	LTP	of	the	striatal	
medium	spiny	neurons,	which	fail	to	depotentiate	(Picconi	et	al.,	2003)	and	also	show	
persistent	deficits	in	LTD	(Picconi	et	al.,	2011).	Clinically,	LTP-like	plasticity	been	detected	in	
the	motor	cortex	which	was	normalised	by	non-LID	inducing	L-DOPA	treatment	(Morgante	
et	al.,	2006)	indicating	that	similar	mechanisms	may	occur	in	patients.	This	plethora	of	
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changes	resulting	from	L-DOPA	treatment	has	a	consequence	for	future	interventions	which	
seek	to	restore	the	neuronal	circuitry.	
L-DOPA	and	cell	transplantation	
Developing	at	a	much	slower	rate,	but	with	the	research	embedded	in	the	same	origins	as	
the	use	of	L-DOPA	as	a	dopamine	replacement	strategy,	a	longer	term,	improved	supply	of	
striatal	dopamine	has	been	explored.	The	principle	of	cell	transplantation	in	Parkinson’s	
disease	is	to	implant	cells	into	the	dopamine-depleted	striatum	to	act	as	a	dopamine	
supplier,	replacing	the	lost	neurotransmitter	and	therefore	restoring	function.	Initial	rodent	
studies	demonstrated	the	feasibility	of	this	approach,	using	either	catecholamine	producing	
adrenal	medulla	tissue	or	dopaminergic	neurons	of	the	developing	foetal	brain	ventral	
mesencephalon	(Perlow	et	al.,	1979;	Björklund	et	al.,	1983;	Freed,	1983).		After	much	
practical	refinement	of	the	approaches,	both	reached	open	label	clinical	trials	in	the	late	
1980’s	(Backlund	et	al.,	1985;	Goetz	et	al.,	1989;	Kelly	et	al.,	1989).	Although	ethically	
compromised,	the	most	clinically	successful	approach	was	the	use	of	early	stage	foetal	
ventral	mesencephalic	cells	to	the	extent	that	several	small	open	label	studies	and	two	US	
government	funded	double	blind	trials	were	delivered	(Lindvall	et	al.,	1990;	Spencer	et	al.,	
1992;	Molina	et	al.,	1994;	Kopyov	et	al.,	1996;	Kopyov	et	al.,	1997;	Levivier	et	al.,	1997;	
Freed	et	al.,	2001;	Hagell	&	Brundin,	2001;	Olanow	et	al.,	2003).			
	
Although	variable,	some	very	successful	outcomes	were	reported	in	the	open	label	trials;	
improvement	in	UPDRS	and	reduction	in	‘off’	time	demonstrated	some	direct	functional	
benefit	with	increases	‘on’	time	in	the	absence	of	dyskinesia	indicative	of	improved	
dopamine	handling	(Lindvall	et	al.,	1990;	Lindvall	et	al.,	1992;	Freeman	et	al.,	1995;	Kopyov	
et	al.,	1997).	One	of	the	best	predictors	for	a	positive	outcome	is	indeed	a	positive	response	
to	L-DOPA	prior	to	transplantation	(Freed	et	al.,	2004).	Unfortunately,	the	double	blind	
clinical	trials	were	disappointing	overall	although	benefit	was	identified	when	patients	were	
stratified	by	age	(Freed	et	al.,	2001;	Olanow	et	al.,	2009).		Some	individuals	have,	over	time,	
significantly	reduced	or	even	ceased	their	L-DOPA	medication	for	a	sustained	period	of	
several	years	before	returning	back	to	the	therapy	(Kefalopoulou	et	al.,	2013).		
	
Graft-induced	dyskinesia	
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Whilst	the	variability	in	post-transplantation	outcomes	was	concerning,	the	first	report	of	
the	double-blind	studies	raised	a	major	issue,	detailing	a	motor	side	effect	now	known	as	
graft-induced	dyskinesia	(Freed	et	al.,	2001).	At	one	year	follow-up	assessments,	5	out	of	33	
grafted	patients,	all	of	whom	had	improved	functionally,	presented	with	involuntary	
movements.	Predominantly	dystonia	in	the	head	and	upper	extremities,	these	movements	
persisted	for	several	days	after	cessation	of	L-DOPA,	in	the	clinically	defined	OFF-phase.	All	
patients	were	under	the	age	of	60	at	the	time	of	transplantation	and	had	pre-existing	LID	in	
response	to	their	ongoing	Parkinson’s	medication	(Freed	et	al.,	2001).		In	a	retrospective	
review	of	video	footage	of	14	patients	who	had	collectively	received	foetal	cell	transplants	
(Hagell	et	al.,	2002),	the	Swedish	team	identified	mild	graft-induced	dyskinesia	in	8	patients	
but	a	further	6	were	considered	to	present	with	moderate,	graft-induced	dyskinesia	with	2	
presenting	with	a	clinically	relevant	problem.		These	persisted	for	up	9	weeks	following	
withdrawal	of	L-dopa.	Phenotypically	the	movements	were	distinct	from	the	
Denver/Colombia	trial,	with	mixed	effects	on	dystonia	but	hyperkinesia	increased	in	all	
patients	and	choreiform	movements	including	brief	dystonic	posturing	alongside	repetitive	
stereotypic	or	ballistic	movements.		In	the	second	of	the	double-blind	studies,	Olanow	and	
colleagues	reported	stereotypic,	rhythmic	graft-induced	dyskinesia	in	56%	(13	out	of	23)	of	
transplant	recipients,	3	of	whom	required	additional	intervention	due	to	their	severity	
(Olanow	et	al.,	2003).		These	additional	interventions	were	varied	with	mixed	degrees	of	
success	which	may	give	some	indications	as	to	the	pathophysiology	but	with	very	limited	
numbers	of	patients	and	limited	information	in	the	public	domain	this	vague	at	best	
(reviewed	in	(Lane	et	al.,	2010).		Typically	deep	brain	stimulation	(DBS)	of	either	the	
subthalamic	nucleus	(STN)	or	the	globus	pallidus	interna	(GPi)	was	attempted	with	STN	DBS	
more	commonly	reported	as	successful	but	no	conclusions	can	really	be	drawn	(Freed	et	al.,	
2001;	Ma	et	al.,	2002;	Cho	et	al.,	2005;	Herzog	et	al.,	2008;	Beaulieu-Boire	&	Fasano,	
2015)(see	figure	1D).		
	
At	the	discovery	of	repeated	incidence	of	graft-induced	dyskinesia,	no	further	clinical	trials	
were	initiated	and	the	imperative	was	to	understand	the	mechanisms	underlying	this	
unprecedented	side	effect.	There	is	no	evidence	that	any	side	effects	of	this	nature	were	
anticipated	form	the	preclinical	work.	Two	reasons	could	underlie	this;	either	that	
spontaneous	dyskinesia	were	simply	not	expressed,	or	that	they	were,	had	not	observed	or	
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reported.		The	majority	of	transplantation	studies	were,	and	continue	to	be,	performed	in	
the	6-OHDA	lesioned	rodent,	a	unilaterally	lesioned	model	in	which	syngeneic	foetal	grafts	
are	easily	produced.	Dopaminergic	restoration	is	readily	monitored	using	both	hand	testing	
for	determinants	of	motor	function	and	drug-induced	rotational	responses	for	objective	
assessment	(reviewed	in	(Lane,	2011).	MPTP-treated	primate	studies	were	also	conducted	
but	logistically	are	far	more	complex	to	perform	foetal	grafting.	As	a	contextual	aside,	the	
methodology	for	evaluating	LID	in	the	MPTP	treated	primate	model	was	well	established	at	
this	time,	and	considered	very	clinically	translatable	(Clarke	et	al.,	1987;	Crossman	et	al.,	
1987).	In	contrast,	whilst	stereotypy	scoring	was	well	established	in	the	rat,	a	representation	
of	dyskinesia	in	the	6-OHDA	lesioned	rat	had	only	recently	been	published	by	Cenci	(1998)	
and	was	still	not	widely	accepted	as	a	clinical	correlate,	although	it	is	now	a	proven	and	
well-established	model.	The	three	clinical	trials	reporting	graft-induced	dyskinesia	varied	in	
many	aspects	(surgical	trajectory,	numbers	of	cells	transplanted,	form	of	the	transplanted	
cells,	storage	of	the	transplanted	cells	prior	to	transplantation,	immunosuppression	post	
transplantation	(Lane,	2011),	but	one	key	commonality	was	that	all	patients	had	pre-existing	
L-DOPA-induced	peak	dose	dyskinesia.		In	addition,	patients	would	continue	to	require	
dopaminergic	pharmacotherapy	following	transplantation	to	a	greater	or	lesser	extent	as	
the	cells	matured.	Only	a	small	number	of	patients	successfully	withdrew	their	anti-
parkinson’s	treatment	completely	as	a	result	of	cell	transplantation	(Kefalopoulou	et	al.,	
2013).		
	
The	role	of	L-DOPA	in	graft-induced	dyskinesia	
Prior	to	the	realisation	of	graft-induced	dyskinesia,	the	only	studies	to	combine	cell	
transplantation	and	L-DOPA	were	designed	to	address	two	very	specific	questions.	The	first	
was	the	potential	toxicity	of	L-DOPA	on	the	grafted	cells	and,	similar	to	the	toxicity	studies	
described	above,	while	in	vitro	toxicity	was	demonstrated	(Alexander	et	al.,	1997),	the	more	
relevant	in	vivo	studies	were	less	conclusive.	Blunt	and	colleagues	showed	that	treatment	of	
rats	with	high	doses	of	L-DOPA	post-graft	did	not	have	a	detrimental	effect	on	graft	survival	
or	functional	activity	(as	measured	by	amphetamine	and	apomorphine-induced	rotations)	
(Blunt	et	al.,	1992).	Conversely,	other	investigators	identified	impaired	cell	survival	and	
morphological	development	of	these	embryonic	dopaminergic	neurons	(Steece-Collier	et	
al.,	1990;	Yurek	et	al.,	1991)	which	was	thought	to	be	driven	by	dopamine	production	rather	
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than	direct	effects	of	L-DOPA	(Alexander	et	al.,	1997).		Prior	to	clinical	trials	only	a	single	
animal	study	explored	whether	grafts	alleviate	LID	showing	a	clear	reduction	in	L-DOPA	
mediated	movements	and	improved	regulation	of	dopamine	(Lee	et	al.,	2000).	However,	no	
study	combined	these	two	questions	and	determined	the	effects	in	the	morphology	and	
function	of	the	graft	in	a	clinically	relevant	paradigm,	i.e.	L-DOPA	administration	with	LID	
generation	and	evaluation	prior	to	transplantation,	with	ongoing	L-DOPA	treatment	
following	the	procedure	and	examination	of	any	dyskinesia	unrelated	to	L-DOPA.		
	
Following	the	revelation	of	graft-induced	dyskinesia,	a	close	examination	of	freely	moving	6-
OHDA	lesioned	rats,	with	established	LID	at	the	time	of	transplantation	with	syngeneic	rat	
ventral	mesencephalon,	showed	the	induction	of	spontaneous	dyskinesia.	The	incidence	of	
the	movements	was	higher	in	those	with	larger	grafts,	and	consisted	of	pronounced	axial	
twisting	contralateral	to	the	lesioned	side	and	forelimb	hyperkinesia	(Lane	et	al.,	2006).	
However,	these	were	generally	mild,	and	were	not	evoked	in	later	test	sessions,	possibly	
due	to	familiarity	with	the	process	and	reduced	stress.	Two,	more	consistent	approaches	
were	determined,	although	both	induce	abnormal	movements	through	pharmacological	
challenge.	During	standardised	amphetamine-induced	rotation	assessment	of	graft	function,	
dyskinetic	movements	were	seen	to	emerge	over	time	post-transplantation,	behaviours	not	
seen	following	amphetamine	in	animals	without	grafts.	Importantly,	these	amphetamine-
induced	behaviours	were	more	prominent	in	L-DOPA	treated	animals	and	correlated	with	
the	severity	of	pre-existing	LID	and	inversely	related	to	the	improvement	in	post-
transplantation	LID	(Carlsson	et	al.,	2006;	Lane	et	al.,	2006;	Lane	et	al.,	2009).	The	second	
approach	was	a	close	examination	of	the	effect	of	transplantation	on	LID	and	despite	global	
improvement,	an	altered	profile	of	LID	has	been	reported	post	transplantation,	with	an	
increase	in	head	movements	and	forelimb	hyperkinesia.		The	paradox	emerges	as	both	
studies	replicated	earlier	findings	of	improved	LID,	simultaneous	with	the	emergence	of	the	
novel,	graft-induced	behaviours.		Indeed,	LID	reduction	occurs	relatively	early	post-
transplantation	compared	to	measures	of	efficacy	of	the	graft	on	motor	function,	suggesting	
that	even	immature	transplanted	neurons	are	able	to	handle	exogenous	L-DOPA	in	
preference	to	the	striatal	5-HT	terminals.	The	consequence	of	this	improved	dopamine	
handling	appears	to	be	a	gradual	normalisation	of	the	post-synaptic	hypersensitivity	to	
dopamine	with	normalisation	of	fosB/DfosB	levels	and	improved	apomorphine-induced	
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rotations	(used	as	an	indication	of	post-synaptic	dopamine	receptor	sensitivity)	(Lane	et	al.,	
2009)	i.e.	normalisation	of	the	processes	that	mediate	LID.		The	driver	underlying	these	
abnormal	behaviours	is	therefore	remains	unclear.		
	
Neither	of	the	rodent	models	gives	a	true	representation	of	graft-induced	dyskinesia	and	
until	recently,	no	studies	had	reported	transplantation	studies	in	MPTP-treated	primates	
with	prior	established	LID,	likely	to	be	the	closest	translational	model	to	the	clinical	
situation.	A	large	MPTP-treated	primate	study	comparing	focal	and	widespread	grafts	
dopaminergic	and	non-dopaminergic	grafts,	with	and	without	L-DOPA	prior	LID	generation,	
confirmed	reduced	LID	following	transplantation.	Frustratingly,	no	spontaneous	graft-
induced	dyskinesia	were	observed	in	this	study	designed	to	determine	whether	L-DOPA	
priming	was	a	key	risk	factor,	thus	leaving	the	search	ongoing	for	the	root	cause	(Kordower	
et	al.,	2017).	However,	L-DOPA	treatment	was	not	continued	post-transplantation,	and	
therefore	it	is	impossible	to	determine	whether	ongoing	L-DOPA	following	transplantation	
would	impact	on	grafted	cell	phenotype,	innervation	or	graft-induced	dyskinesia.		
	
The	effect	of	L-DOPA	on	the	maturation	and	survival	of	transplanted	cells	was	evaluated	in	a	
small	number	of	studies	prior	to	clinical	trials	but	this	has	been	revisited	since	the	
revelations	of	graft-induced	dyskinesia.	Comparing	initiation	of	L-DOPA	treatment	from	
either	5	weeks	pre	or	9	weeks	post-transplantation	found	that	pre-exposure	to	chronic	L-
DOPA	had	no	effect	on	cell	survival	significantly	reduced	both	behavioural	and	
neurochemical	efficacy	of	embryonic	dopamine	grafts	(Steece-Collier	et	al.,	2009).	A	second	
study	compared	pre-	and	post-transplantation	treatment	with	L-DOPA	with	two	graft	types,	
an	allogeneic	vs	xenogeneic	graft.	While	graft	integrity	was	unaffected	by	L-DOPA,	
inflammatory	responses	were	higher	if	L-DOPA	was	administered	with	a	less	
immunologically	compatible	graft	(mouse	derived	ventral	mesencephalon)	(Breger	et	al.,	
2017).	As	in	the	previous	rodent	studies,	the	MPTP	non	human	primate	study	also	
demonstrate	that	an	L-DOPA	primed	striatum	is	not	a	more	aversive	environment	for	
transplanted	foetal	cells	with	no	difference	in	transplant	survival	between	L-DOPA	primed	
and	L-DOPA	naïve	primates	(Steece-Collier	et	al.,	2009;	Breger	et	al.,	2017;	Kordower	et	al.,	
2017).		
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However,	overall	we	still	do	not	have	model	representation	of	true	graft-induced	dyskinesia,		
perhaps	due	to	over-simplification	of	the	models,	Graft-induced	dyskinesia	is	unlikely	to	be	
driven	by	a	single	factor,	using	multi-factorial	approaches	may	be	necessary	to	determine	
whether	there	is	a	clinically	meaningful	effect	of	L-DOPA	on	grafts.		The	role	of	endogenous	
and	exogenous	5-HT	innervation	from	the	host	or	within	the	graft	has	been	the	focus	of	a	
lot	of	speculation	in	relation	to	both	LID	and	graft-induced	dyskinesia.	A	detailed	discussion	
is	beyond	the	scope	of	this	review	and	is	discussed	elsewhere	(see	(Shin	et	al.,	2012a;	
Niccolini	et	al.,	2014),	but	in	brief,	there	is	a	high	degree	of	endogenous	striatal	serotonergic	
innervation	which	is	enhanced	following	foetal	cell	transplantation.		While	there	is	strong	
evidence	that	L-DOPA	management	through	the	endogenous	striatal	innervation	
contributes	to	dysregulation	of	L-DOPA	handling	and	thus	LID	(Carta	&	Björklund,	2018),	the	
picture	in	relation	to	graft-induced	dyskinesia	is	less	convincing.	Clinical	imaging	evidence	of	
high	striatal	5-HT	transporter	density	in	transplanted	patients	with	graft-induced	dyskinesia	
is	assumed	to	arise	from	‘contamination’	of	the	graft	material	by	the	neighbouring	dorsal	
raphe	(Politis	et	al.,	2010a;	Politis	et	al.,	2011).	Upon	administration	of	the	5-HT1A	receptor	
antagonist	buspirone,	grafted	patients	showed	reduced	expression	of	the	induced	
dyskinesia,	although	this	could	be	explained	by	the	dopamine	D2	receptor	partial	agonist	
activity	of	the	drug	leading	to	antagonist	actions	in	high	dopamine	areas	(Politis	et	al.,	
2010a;	Shin	et	al.,	2012b).	Importantly,	in	the	study	by	Politis	and	colleagues	(2010a),	no	
patient	with	a	graft	without	the	side	effect	underwent	scanning	as	a	comparator	and	post	
mortem	data	from	a	Canadian	transplanted	cohort	showed	high	striatal	5-HT	transporter	
content	in	the	absence	of	graft-induced	dyskinesia	(Mendez	et	al.,	2005).	The	
aforementioned	reduction	in	dyskinesia	with	buspirone	was	not	reproduced	in	a	patient	
from	a	different	transplanted	cohort	(Beaulieu-Boire	&	Fasano,	2015).			
	
A	detailed	phenotypic	analysis	of	grafts	matured	in	the	presence	of	L-DOPA	administration	is	
yet	to	be	conducted,	an	excellent	study	of	synapse	formation	has	been	performed	
producing	interesting	insights	(Soderstrom	et	al.,	2008).	Dopamine	depletion	in	the	striatum	
and	LID	generation	cause	loss	of	spines	on	the	medium	spiny	neurons,	the	site	of	normal	
synapse	formation	with	the	dopaminergic	nigrostriatal	innervation.		Transplanted	neurons	
appear	to	form	asymmetric	synapses	on	the	soma	as	a	result,	and	these	have	been	linked	to	
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abnormal	post-transplantation	responses	to	L-DOPA	(Soderstrom	et	al.,	2008).		Dendritic	
spine	loss	occurs	via	dysregulation	of	intraspine	Cav1.3	L-type	Ca(2+)channels	and	can	be	
prevented,	in	animal	models,	by	administration	of	the	calcium	channel	antagonist,	
nimodipine.	When	this	was	administered	maintained	spine	integrity	led	to	improved	motor	
performance	and	reduction	in	L-DOPA-induced	abnormal	movements	which	supports	the	
concept	that	the	emergent	abnormalities	following	transplantation	in	response	to	L-DOPA	
result	from	incomplete	reinnervation	rather	than	aberrant	neuronal	activity	(Soderstrom	et	
al.,	2010).	Clearly	the	ability	of	the	transplanted	neurons	to	reform	the	deficit	neuronal	
circuitry	is	compromised	by	L-DOPA,	but	the	clinical	implications	of	this	remain	unclear.			
	
To	date,	the	majority	of	preclinical	animal	studies	exploring	the	interplay	between	cells	and	
drug	treatments	have	utilised	transplantation	of	primary	ventral	mesencephalon.	The	next	
evolution	of	this	work	must	be	to	examine	the	impact	of	L-DOPA	and	dopaminergic	drugs	on	
the	transplantation	of	cells	from	other	sources,	primarily	the	human	embryonic	stem	cells	
that	will	be	used	in	upcoming	clinical	trials	in	the	US	(NYSTEM)	and	Europe	(STEM-PD)	
(Kirkeby	et	al.,	2017;	Studer,	2017).	Stem	cells	carry	dopamine	receptors	throughout	
differentiation.		Both	dopamine	and	5-HT	are	known	regulators	of	neurogenesis	both	in	vivo	
and	in	vitro	(Takamura	et	al.,	2014),	and	as	such	clearly	have	the	potential	to	regulate	the	
proliferation	and	differentiation	of	implanted	stem	cells.	Dopamine	receptors,	in	particular,	
the	D2-like	receptor	family,	are	expressed	at	all	stages	of	dopaminergic	differentiation	of	H9	
stem	cells	and	dopamine	agonists	have	been	shown	to	alter	proliferation,	phenotype	and	
neurite	outgrowth	in	vitro	(Belinsky	et	al.,	2013).	In	vitro	exposure	to	dopamine	late	in	the	
differentiation	process	(around	the	time	cells	might	be	transplanted)	caused	a	dopamine	D2	
receptor	dependent	increase	in	TH-positive	clusters	of	cells	and	doubling	of	neurite	
formation	(Belinsky	et	al.,	2013).		This	work	is	complicated	by	the	need	to	transplant	
xenogeneically,	to	study	the	human	cells	in	rats	and	although	there	are	some	strategies	to	
facilitate	this	(the	use	of	immunosuppression,	immunodeficient	rats	or	neonatal	
densensitisation)	each	has	its	problems.	Inflammation	may	be	an	important	cofactor	to	be	
considered	alongside	L-DOPA	but	it	unclear	whether	this	is	feasible	in	a	rodent	model	in	a	
clinically	relevant	fashion.		Both	NYSTEM	and	STEM-PD	trials	indicate	that	due	to	the	‘first	in	
man’	nature	of	these	studies	they	are	likely	to	be	recruiting	patients	with	established	
moderate	Parkinson’s	disease	are	therefore	likely	to	have	pre-existing	LID	(Kirkeby	et	al.,	
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2017;	Studer,	2017).	The	outcomes	of	TransEUro,	a	clinical	study	designed	with	the	
improved	knowledge	around	graft-induced	dyskinesia	(Moore	et	al.,	2014),	and	of	these	
new	stem	cell	trials	themselves	will	be	hugely	enlightening.		
	
The	future	of	L-DOPA	
Despite	its	array	of	problems,	L-DOPA	has	still	not	been	bettered	as	a	symptomatic	
treatment.	There	is	still	traction,	therefore,	in	circumventing	the	acute	and/or	chronic	side	
effects	through	improved	delivery	systems.	One	new	oral	approach	has	been	approved,	
IPX066,	which	is	an	extended	release	L-DOPA/carbidopa	capsule	formulation	(Hauser	et	al.,	
2018).	Oral	therapy	has	highly	variable	gastrointestinal	absorption	leading	to	vast	
differences	in	plasma	levels	from	dose	to	dose,	some	of	which	may	be	attributable	to	
delayed	gastric	emptying	and	other	gut	abnormalities.	There	is	currently	the	option,	in	
severe	disease	with	motor	complication,	to	administer	the	drug	through	an	intrajejunal	
route	using	the	DuoDopa	pump.		This	has	been	shown	to	have	sustained	beneficial	effects	
on	both	motor	and	non-motor	symptoms	using	an	L-DOPA/carbidopa	gel	formulation.	A	
trigel	formulation	with	the	addition	of	entacapone	is	currently	in	development,	which	may	
add	increased	clinical	benefit	(Senek	et	al.,	2017).		New	formulations	in	clinical	trials	
currently	include	inhaled	(CVT-301)	(Lipp	et	al.,	2016)	for	management	of	‘OFF-phase’	and	
liquid	for	subcutaneous	administration	(ND0612)	as	a	patch-pump.	ND0612	is	being	
developed	for	moderate	and	severe	disease	and	could	produce	much	improved	control	of	
plasma	L-DOPA	levels	and	therefore	dyskinesia	(Freitas	et	al.,	2016;	Ramot	et	al.,	2017).		
	
Conclusions	
L-DOPA	is	a	high	effective	drug	that	has	been	widely	used	for	over	50	years	and	will	
continue	as	the	mainstay	of	Parkinson’s	disease	therapy	for	many	years	to	come.		New	
formulations	may	extend	its	lifetime	still	further	and	hopefully	will	help	manage	some	of	the	
treatment-limiting	side	effects	that	are	so	problematic	in	advanced	disease.	Despite	its	
longevity,	it	is	clear	that	there	is	much	we	do	not	understand	about	the	mechanisms	
underlying	both	the	therapeutic	and	negative	effects.		Neuronal	circuitry	and	function	is	
altered	through	chronic	L-DOPA	treatment	and	while	cell	transplantation	teaches	us	that	
this	can	be	reversed,	this	opens	up	new	questions	about	alternative	pathways	that	might	be	
generating	motor	side	effects.	The	lessons	from	the	cell	transplantation	experience	is	that,	
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at	the	very	least,	we	must	be	alert	to	the	potential	consequence	of	L-DOPA	and	the	
consequent	dyskinesia	in	novel	reparative	and	neuroprotective	strategies	and	consider	how	
we	factor	this	in	to	preclinical	models.		
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Figure	1	
	
Illustration	of	postulated	basal	ganglia	physiology	and	pathophysiology	in	Parkinson’s	
disease,	L-DOPA	induced	dyskinesia	and	graft-induced	dyskinesia.		Described	originally	by	
(Albin	et	al.,	1989),	this	figure	illustrates	the	dopaminergic	nigrostriatal	innervation	of	the	
GABAergic	medium	spiny	neurons	(MSNs)	of	the	striatum.	These	MSNs	form	two	output	
pathways;	direct	pathway	directly	innervating	the	GPi/SNr	output	nuclei	under	the	control	
of	D1	dopamine	receptors;	indirect	pathway	innervating	the	GPe	under	the	control	of	the	
D2	dopamine	receptors.	The	indirect	pathway	then	regulates	the	GPi/SNr	via	the	STN.	
GABAergic	regulation	of	the	thalamus	by	the	output	nuclei	then	regulates	cortical	activity	
and	motor	function	(many	reciprocal	pathways	exist	and	have	not	been	shown	for	clarity).	
B)	Cortical	control	is	disrupted	by	the	loss	of	nigrostriatal	dopamine	in	Parkinson’s	disease,	
the	consequences	of	which	is	increased	inhibitory	input	to	the	thalamus	and	lowered	
cortical	excitation	reducing	movement.		C)	L-DOPA-induced	dyskinesia	arise	through	the	
excessive	activity	at	the	GPi/SNr	disinhibiting	the	thalamus	leading	to	excessive	cortical	
stimulation.	D)	While	it	is	evident	there	is	excessive	cortical	drive,	there	is	still	no	clarity	
about	the	activity	of	the	basal	ganglia	nuclei	during	graft-induced	dyskinesia	given	that	for	
many	patients	it	occurs	simultaneous	with	improved	function	(although	not	necessarily).		
	
(STN=	subthalamic	nucleus,	GPi	–	globus	pallidus	interna,	GPe	–	globus	pallidus	externa,	SNr	
–	substantia	nigra	pars	reticulata,	SNc	–	substantia	nigra	pars	compacta	
	
	
Abbreviations:	
6-OHDA	-	6-hydroxydopamine	
DBS	-	deep	brain	stimulation	
L-DOPA	-	3,4-dihydroxy-L-phenylalanine	
LID	-	L-DOPA-induced	dyskinesia	
MPTP	–	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	
SNc	–	substantia	nigra	pars	compacta	
STN	-	subthalamic	nucleus	
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